216 related articles for article (PubMed ID: 14734736)
1. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
2. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
Dace DS; Chen PW; Niederkorn JY
J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
[TBL] [Abstract][Full Text] [Related]
3. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
5. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
6. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
Ksander BR; Mammolenti MM; Streilein JW
Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of an intraocular tumor in mice.
Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye.
McKenna KC; Kapp JA
J Immunol; 2006 Aug; 177(3):1599-608. PubMed ID: 16849468
[TBL] [Abstract][Full Text] [Related]
9. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection.
Chen PW; Uno T; Ksander BR
J Immunol; 2006 Jul; 177(1):162-8. PubMed ID: 16785511
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of immune tolerance depends on normal tissue homeostasis.
Boonman ZF; van Mierlo GJ; Fransen MF; de Keizer RJ; Jager MJ; Melief CJ; Toes RE
J Immunol; 2005 Oct; 175(7):4247-54. PubMed ID: 16177064
[TBL] [Abstract][Full Text] [Related]
12. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
13. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
[TBL] [Abstract][Full Text] [Related]
14. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
15. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
Ligocki AJ; Brown JR; Niederkorn JY
J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
[TBL] [Abstract][Full Text] [Related]
16. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8+ T cells.
McKenna KC; Xu Y; Kapp JA
J Immunol; 2002 Nov; 169(10):5630-7. PubMed ID: 12421942
[TBL] [Abstract][Full Text] [Related]
17. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
18. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.
Coles RM; Mueller SN; Heath WR; Carbone FR; Brooks AG
J Immunol; 2002 Jan; 168(2):834-8. PubMed ID: 11777979
[TBL] [Abstract][Full Text] [Related]
19. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.
den Boer AT; Diehl L; van Mierlo GJ; van der Voort EI; Fransen MF; Krimpenfort P; Melief CJ; Offringa R; Toes RE
J Immunol; 2001 Sep; 167(5):2522-8. PubMed ID: 11509591
[TBL] [Abstract][Full Text] [Related]
20. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
